Please login to the form below

Not currently logged in
Email:
Password:

Cancer disruptor F Star names next CEO

Dr Eliot Forster takes reins from Dr John Haurum

UK-based biotech F-star has named Dr Eliot Forster as its new chief executive.

Foster

Dr Eliot Forster, Incoming F-Star CEO

Based at the Babraham Research Campus in the Cambridge biotech cluster, the firm has been under the leadership of Dr John Haurum since it was set up in 2006. He is now handing over to Forster, who recently left another UK biotech, Oxford-based Immunocore.

While Immunocore is focused on novel immuno-oncology drugs, F-star specialises a new generation of bispecific antibodies, with cancer also its prime focus.

F-star has two assets in development, including its lead first-in-class, Merck KGaA-partnered candidate FS118, which works by simultaneously blocking two tumour growth promoting immune checkpoint molecules.

Dr Eliot Forster has been in the sector for more than 25 years, having served in senior positions for Pfizer and GSK.

At Immunocore, he helped the company raise a huge $320m during in a series A financing round – a feat which he may aim to duplicate at his new company.

“Over recent years, IO has transformed the oncology treatment paradigm, offering significantly better options to patients,” he says.

“The co-administration of immunotherapies is expected to be the next cornerstone in cancer treatments. I believe that F-star’s first-in-class molecules bring together in a single form, the full power of IO and combinations. We anticipate this synergistic benefit will deliver more targeted, potent and safer treatment options for cancer patients.”

The company has deals with the likes of Bristol-Myers Squibb, Merck KGaA and AbbVie.

16th October 2018

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Creative Medical Research

Specialising in medical device market research and participant recruitment human factors research, our approach is people-centric. We thrive on making...

Latest intelligence

What is changing in cardiovascular disease care?
Paul Midgley, of Wilmington Healthcare, explores the NHS Long-term Plan’s strategy for tackling cardiovascular disease and what it means for pharma...
PANDAS/PANS Awareness: A parent’s story
To help raise awareness of these often underdiagnosed diseases, Jon Hallows, Joint MD at Porterhouse shares his own experience as a parent of a son recently diagnosed with PANDAS...
Iskra Reic
Leading AstraZeneca’s return to growth in Europe
PME talks to Iskra Reic, the company’s head of Europe and Canada...

Infographics